Back to Browse Journals » Journal of Asthma and Allergy » Volume 4

Clinical update on the use of biomarkers of airway inflammation in the management of asthma

Authors Wadsworth SJ, Sin DD, Dorscheid DR

Published Date June 2011 Volume 2011:4 Pages 77—86

DOI http://dx.doi.org/10.2147/JAA.S15081

Published 30 June 2011

SJ Wadsworth1,2, DD Sin1,2, DR Dorscheid1,2
1UBC James Hogg Research Centre, Providence Heart and Lung Institute, St Paul's Hospital, Vancouver, Canada; 2Department of Medicine, University of British Columbia, British Columbia, Canada

Abstract: Biological markers are already used in the diagnosis and treatment of cardiovascular disease and cancer. Biomarkers have great potential use in the clinic as a noninvasive means to make more accurate diagnoses, monitor disease progression, and create personalized treatment regimes. Asthma is a heterogeneous disease with several different phenotypes, generally triggered by multiple gene-environment interactions. Pulmonary function tests are most often used objectively to confirm the diagnosis. However, airflow obstruction can be variable and thus missed using spirometry. Furthermore, lung function measurements may not reflect the precise underlying pathological processes responsible for different phenotypes. Inhaled corticosteroids and ß2-agonists have been the mainstay of asthma therapy for over 30 years, but the heterogeneity of the disease means not all asthmatics respond to the same treatment. High costs and undesired side effects of drugs also drive the need for better targeted treatment of asthma. Biomarkers have the potential to indicate an individual's disease phenotype and thereby guide clinicians in their decisions regarding treatment. This review focuses on biomarkers of airway inflammation which may help us to identify, monitor, and guide treatment of asthmatics. We discuss biomarkers obtained from multiple physiological sources, including sputum, exhaled gases, exhaled breath condensate, serum, and urine. We discuss the inherent limitations and benefits of using biomarkers in a heterogeneous disease such as asthma. We also discuss how we may modify our study designs to improve the identification and potential use of potential biomarkers in asthma.

Keywords: asthma, inflammation, airway biomarkers, urinary biomarkers, serum biomarkers

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Cost-effectiveness analysis on the use of rFSH + rLH for the treatment of anovulation in hypogonadotropic hypogonadal women

Papaleo E, Alviggi C, Colombo GL, Pisanelli C, Ripellino C, Longobardi S, Canonico PL

Therapeutics and Clinical Risk Management 2014, 10:479-484

Published Date: 25 June 2014

A scalable fabrication process of polymer microneedles

Yang S, Feng Y, Zhang L, Chen N, Yuan W, Jin T

International Journal of Nanomedicine 2012, 7:1415-1422

Published Date: 12 March 2012

Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size

Nishimura Y, Taguchi M, Nagai T, Fujihara M, Honda S, Uenishi M

Clinical Ophthalmology 2012, 6:365-368

Published Date: 6 March 2012

Fe3O4/Au magnetic nanoparticle amplification strategies for ultrasensitive electrochemical immunoassay of alfa-fetoprotein

Gan N, Jin H, Li T, Zheng L

International Journal of Nanomedicine 2011, 6:3259-3269

Published Date: 9 December 2011

Adjusting for COPD severity in database research: developing and validating an algorithm

Goossens LMA, Baker CL, Monz BU, Zou KH, Rutten-van Mölken MPMH

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:669-678

Published Date: 6 December 2011

The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals

Men Y, Wang XX, Li RJ, Zhang Y, Tian W, Yao HJ, Ju RJ, Ying X, Zhou J, Li N, Zhang L, Yu Y, Lu WL

International Journal of Nanomedicine 2011, 6:3125-3137

Published Date: 2 December 2011

Treatment of Parkinson's disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system

Tessy López, José L Bata-García, Dulce Esquivel, et al

International Journal of Nanomedicine 2011, 6:19-31

Published Date: 16 December 2010

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

ATP8A1 activity and phosphatidylserine transbilayer movement

Eric Soupene, Dwi Utami Kemaladewi, Frans A Kuypers

Journal of Receptor, Ligand and Channel Research 2008, 1:1-10

Published Date: 22 September 2008